Efficacy and safety of re-challenging 160 mg furmonertinib for advanced NSCLC after resistance to third-generation EGFR-TKIs targeted agents: A real-world study

• DOI: 10.1016/j.lungcan.2023.107346
• Publication Date: 2023-08-17T00:51:37Z
• Authors: Rongbin Qi; Xinyu Fu; Yingying Yu; Hailing Xu; Mo Shen; Susu He; Dongqing Lv
• Keywords: Progression-free survival; T790M

Third-generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKI) show good selectivity for classical EGFR mutated and T790M non-small cell lung cancer (NSCLC). However, resistance inevitably occurs to third-generation EGFR-TKI. This study describes the real-world characteristics, efficacy, safety of treating post-progression NSCLC with 160 mg furmonertinib (in combination or without anti-angiogenic agents chemotherapy) EGFR-TKIs.EGFR-mutated patients intracranial progression pattern cohort (IP cohort) extracranial (EP were retrospectively analyzed following EGFR-TKIs receiving daily as second-line later treatment in chemotherapy.Thirty-nine included categorized into two groups according pattern. Then, 22 IP 17 EP cohort, most whom poor physical condition, 84.6% had central nervous system metastases. In median PFS was 5.5 months (95% CI 4.67-8.72), OS 9.8 7.25-11.20) single-agent therapy. 3.2 2.18-4.70), 6.7 4.99-8.75). Univariate analysis showed association between presence a prior mutation history combined radiotherapy longer (p = 0.048, p 0.004). Overall, adverse events (AEs) any grade occurred (33/39), majority having 2 lower AEs.Furmonertinib is an optional regimen advanced who develop after EGFR-TKIs, especially those developing due lesions, efficacy acceptable profile that warrants further exploration.